Skip to Content
Merck
CN

Y0001173

Filgrastim

European Pharmacopoeia (EP) Reference Standard

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

CAS Number:
UNSPSC Code:
41116107
NACRES:
NA.24
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

pharmaceutical primary standard

API family

filgrastim

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

−70°C

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Filgrastim EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

常规特殊物品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ann M Farese et al.
Radiation research, 179(1), 89-100 (2012-12-06)
Treatment of individuals exposed to potentially lethal doses of radiation is of paramount concern to health professionals and government agencies. We evaluated the efficacy of filgrastim to increase survival of nonhuman primates (NHP) exposed to an approximate mid-lethal dose (LD(50/60))
Simone Cesaro et al.
PloS one, 8(1), e53252-e53252 (2013-01-12)
To assess the non-inferiority of pegfilgrastim versus filgrastim in speeding the recovery of polymorphonuclear cells (PMN) in pediatric patients who underwent autologous peripheral blood stem cell transplant (PBSCT). The sample size of this randomized, multicenter, phase III study, was calculated
L M Rozhdestvenskiĭ et al.
Radiatsionnaia biologiia, radioecologiia, 53(1), 47-54 (2013-05-25)
We have evaluated the treatment effectiveness of Leucostim and Neupomax in dogs exposed to radiation at lethal doses of 3 and 3.5 Gy, correspondingly, by testing the dynamics of the blood cell number, first of all, leucocytes and neutrophiles, and
I A Puchkov et al.
Bioorganicheskaia khimiia, 38(5), 545-554 (2013-01-25)
In order to create an active pharmaceutical substance of the drug with prolonged action the modification of recombinant human granulocyte colony-stimulating factor GCSF (filgrastim) with polyethylene glycol (PEG, M 21.5 kDa) was conducted. A method for preparation of PEG-filgrastim designed
I Ia Moiseeva et al.
Voprosy onkologii, 59(2), 71-74 (2013-07-03)
There was studied the influence Dicarbamine and Leykostime on peripheral blood leukocyte composition of rabbits in experimental radiogenic damage to the blood system. Dicarbamine significantly insured the safety of circulating red blood cells, prevented the development of severe postradiation thrombocytopenia

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service